Cancer News
OncoLink Cancer News - HealthDay


Treatments with exemestane alone or following tamoxifen have different side effects

Tuesday, January 18, 2011 (Last Updated: 01/19/2011)

TUESDAY, Jan. 18 (HealthDay News) -- Adjuvant breast cancer therapy with an aromatase inhibitor (exemestane) alone, or used following tamoxifen, offers similar disease-free survival rates but different side-effect profiles, according to a study published online Jan. 18 in The Lancet.

Cornelis J.H. van de Velde, M.D., of Leiden University Medical Centre in the Netherlands, and colleagues conducted the Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase-3 clinical trial in nine countries, which studied the effects of exemestane alone (25 mg daily) or following tamoxifen (20 mg daily), in postmenopausal women with hormone-receptor-positive breast cancer. A total of 9,779 women were randomized 1:1 to each group and followed for five years.

The researchers found similar disease-free rates in the two groups at five years: 85 percent in the sequential group and 86 percent in the exemestane-alone group (hazard ratio, 0.97; P = 0.60). In the safety analysis, sequential treatment was associated with a higher incidence of gynecological symptoms (20 versus 11 percent), venous thrombosis (2 versus 1 percent), and endometrial abnormalities (4 versus <1 percent) than with exemestane alone. Exemestane alone was associated with a higher incidence of musculoskeletal adverse events (50 versus 44 percent), hypertension (6 versus 5 percent), and hyperlipidemia (5 versus 3 percent).

"Because of the differences in profiles of the adverse events between exemestane monotherapy and sequential treatment (tamoxifen followed by exemestane), consideration of the safety of these treatment strategies might play an important part in treatment decisions," the authors write.

The study was funded by Pfizer; several authors disclosed financial ties to pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)

Specialties Hematology & Oncology
OBGYN & Women's Health
Pharmacy

Copyright © 2011 HealthDay. All rights reserved.


I Wish You Knew

Screening with Mammography: Looking at the Controversy

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More